OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
17
Results
Show all
Save search
Copy query
Show results for
Unknown
(17)
Publication Date
Release Date
2021
(6)
2025
(4)
2022
(4)
2024
(1)
2023
(1)
2019
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Awake prone positioning and oxygen therapy in patients with COVID-19: the APRONOX study.
Not available
S-EPMC8576803
|
biostudies-literature
Cite
Genes and Variants Underlying Human Congenital Lactic Acidosis-From Genetics to Personalized Treatment.
Not available
S-EPMC6912785
|
biostudies-literature
Cite
Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
Not available
S-EPMC12034854
|
biostudies-literature
Cite
Variation in wood density across South American tropical forests.
Not available
S-EPMC11893774
|
biostudies-literature
Cite
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Not available
S-EPMC7727327
|
biostudies-literature
Cite
Ketamine, Etomidate, and Mortality in Emergency Department Intubations.
Not available
S-EPMC12706683
|
biostudies-literature
Cite
Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 Registry.
Not available
S-EPMC11882944
|
biostudies-literature
Cite
Validation of the RIM Score-COVID in the Spanish SEMI-COVID-19 Registry.
Not available
S-EPMC9862219
|
biostudies-literature
Cite
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604
|
biostudies-literature
Cite
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets